Automation Anywhere is a leading provider of robotic process automation (RPA) designed to work side by side with people to handle repetitive routines and tasks. The Company’s automation platform provides bots, powered by AI, trained to automate process steps running on any application. Through Automation Anywhere’s platform, businesses can scale processes faster, with near-zero error rates, while dramatically reducing operational costs. As of December 2020, Automation Anywhere has deployed over 2.6 million bots to support over 3,500 of the world’s largest enterprises, including GM, Cisco, Google, Huawei, FedEx, MasterCard and other world-famous enterprise customers.
ThoughtSpot is a leading business intelligence analytics platform. It offers large-scale enterprises with search and data analysis driven by artificial intelligence, allowing users to tap into invaluable charts and insights via a simple search query. Through ThoughtSpot, non-technical business decision makers can access deep data analytics without going through complex and cumbersome processes with data scientists and analysts. ThoughtSpot’s analytical service solutions help make decision making up to 85% more efficient compared to other incumbent business intelligence platforms.
23andMe is a leading genetic testing and healthcare company that helps consumers access, understand, and benefit from the human genome. 23andMe offers 2 key products to consumers: “Ancestry Test Kits” and “Ancestry + Genetic Health Test Full Suite Kits”. Through these testing products, customers can receive comprehensive risk assessment report on their likelihood of developing genetically influenced diseases, including Parkinson’s, Alzheimer’s, Breast Cancer, Ovarian Cancer, Prostate Cancer, diabetes, and a number of other chronic illnesses. As of December 2020, the Company’s products are offered in 52 countries, its number of genetic profiles have surpassed 12 million profiles, and is approved to issue more than 55 health reports. 23andMe maintains strategic co-drug development partnerships with large-scale pharmaceutical companies such as Genentech, Pfizer, and GSK. Additionally, 23andMe is currently developing 13 proprietary candidates within its own drug pipeline.